Session Details
[1S03a]Towards the development of personalized therapy strategies based on the pathological analyses of intractable arrhythmias and cardiomyopathies
Tue. Mar 10, 2026 2:30 PM - 4:20 PM JST
Tue. Mar 10, 2026 5:30 AM - 7:20 AM UTC
Tue. Mar 10, 2026 5:30 AM - 7:20 AM UTC
Room 3(School of Nursing Building, 2F, 201)
Organizers: Hiroko Izumi-Nakaseko (Toho University), Yukiko Himeno (The University of Osaka)
Chairs: Takeru Makiyama (Kyoto University), Yukiko Himeno (The University of Osaka)
Chairs: Takeru Makiyama (Kyoto University), Yukiko Himeno (The University of Osaka)
Both congenital and acquired factors are variously involved in the pathogenesis of intractable arrhythmias and cardiomyopathies. Genetic mutations in ion channels and contraction-related proteins are representative of congenital factors, while acquired factors such as therapeutic drugs and lifestyles further increase disease risk. Identification of individual molecular and electrophysiological mechanisms underlying these pathological drivers can help identify the tipping point for disease onset. This symposium will highlight studies on gene mutations linked to early repolarization syndrome, which causes fatal arrhythmias; mechanism of drug-induced arrhythmias; mathematical modeling of the pathophysiology of cardiomyocytes; and related drug discovery efforts. This approach will provide an integrated understanding of cardiac dysfunction and advance the development of personalized, clinically applicable therapies.
Introduction
[1S03a-01]Analysis of the arrhythmogenic properties of anticancer drugs using human iPS-derived cardiomyocyte sheets: comparison with multichannel blockers
*Hiroko Izumi-Nakaseko1, Yuko Sekino2,3, Ryuichi Kambayashi1, Ai Goto1, Yoshinori Takei4, Yukiko Himeno5,6, Ayako Okado-Matsumoto7, Yoshinobu Nagasawa8, Atsuhiko T. Naito9, Yasunari Kanda10, Atsushi Sugiyama1,11, Tatsuya Morimoto1 (1. Dept. Pharmaco., Fac. Med., Toho Univ., 2. Grad. Sch. Agric. Life Sci., Univ. Tokyo, 3. Inst. Drug Discovery Innov., 4. Dept. Translational Research & Cellular Therapeutics, Fac. Med., Toho Univ., 5. Premium Res. Inst. Human Metaverse Med., Univ. Osaka, 6. Res. Org. Sci. Tech., Ritsumeikan Univ., 7. Lab. Biochem., Dept. Biol., Fac. Sci., Toho Univ., 8. Dept. Pharmacol. Ther., Fac. Pharmaceutical Sci., Toho Univ., 9. Dept. Physiol., Div. Cell Physiol., Grad. Sch. Med., Toho Univ., 10. Div. Pharmacol., NIHS, 11. Yamanashi Res. Ctr. Clinic. Pharmacol.)
Q&A
[1S03a-02]KCND3 variants as a Cause of Early Repolarization and Epilepsy: Mechanistic Elucidation and Drug Repositioning
*Tserenlkham Byambajav1,2, Takeru Makiyama3, Koichiro Takayama1, Hai Huang3, Minoru Horie4, Seiko Ohno1 (1. Medical Genome Center, National Cerebral and Cardiovascular Center, Japan, 2. Laboratory of Epidemiology and Prevention, Kobe Pharmaceutical University, Japan, 3. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto University, Japan, 4. Department of Cardiovascular Medicine, Shiga University of Medical Science, Japan)
Q&A
[1S03a-03]Abnormal Ca2+ signals, arrhythmias, and cardiomyopathy caused by hyperactivity of RyR2
*Nagomi Kurebayashi1 (1. Dept Pharmacol, Juntendo Univ Fac Med)
Q&A
[1S03a-04]Mathematical analysis of arrythmia with mathematical models
*Akira AMANO1, Yukiko Himeno2, Hiroko Izumi-Nakaseko3, Kunichika Tsumoto4 (1. Ritsumeikan University, 2. Osaka University, 3. Toho University, 4. Kanazawa Medical University)
